PRESS-RELEASE filed Mar 10, 2026 at 06:45 ET
BioNTech reported full-year 2025 revenues of €2.87 billion, up 4.3% YoY, but posted a net loss of €1.14 billion (€4.70 diluted loss per share), widening from a €665.3 million loss in 2024. The quarterly revenue declined 23.7% due to lower COVID-19 vaccine demand, and the company issued 2026 revenue guidance of €2.0–2.3 billion, signaling a further decline. Despite a strong cash position of €17.2 billion, the outlook reflects continued transition from pandemic-era revenues to oncology-focused R&D, with multiple late-stage readouts expected in 2026.